Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy

被引：3

作者：

Chunmei Fan ^{[1
,2
,3
]}

Shanshan Zhang ^{[4
]}

Zhaojian Gong ^{[5
]}

Xiayu Li ^{[3
]}

Bo Xiang ^{[1
,2
]}

Hao Deng ^{[3
]}

Ming Zhou ^{[1
,2
]}

Guiyuan Li ^{[1
,2
]}

Yong Li ^{[6
]}

Wei Xiong ^{[1
,2
]}

Zhaoyang Zeng ^{[1
,2
]}

Xiaoling Li ^{[1
,2
]}

机构：

[1] NHC Key Laboratory of Carcinogenesis,Hunan Cancer Hospital and the Affiliated Cancer Hospital,Xiangya School of Medicine,Central South University

[2] Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education,Cancer Research Institute and School of Basic Medical Science,Central South University

[3] Hunan Key Laboratory of Nonresolving Inflammation and Cancer,Disease Genome Research Center,the Third Xiangya Hospital,Central South University

[4] Department of Stomatology,Xiangya Hospital,Central South University

[5] Department of Oral and Maxillofacial Surgery,The Second Xiangya Hospital,Central South University

[6] Department of Medicine,Dan L Duncan Comprehensive Cancer Center,Baylor College of Medicine

来源：

Science China(Life Sciences) | 2021年 / 04期

关键词：

D O I：

暂无

中图分类号：

R730.51 [免疫疗法];

学科分类号：

100214 ;

摘要：

Mounting evidence has revealed that the therapeutic efficacy of immunotherapies is restricted to a small portion of cancer patients. A deeper understanding of how metabolic reprogramming in the tumor microenvironment(TME) regulates immunity remains a major challenge to tumor eradication. It has been suggested that metabolic reprogramming in the TME may affect metabolism in immune cells and subsequently suppress immune function. Tumor cells compete with infiltrating immune cells for nutrients and metabolites. Notably, the immunosuppressive TME is characterized by catabolic and anabolic processes that are critical for immune cell function, and elevated inhibitory signals may favor cancer immune evasion. The major energy sources that supply different immune cell subtypes also undergo reprogramming. We herein summarize the metabolic remodeling in tumor cells and different immune cell subtypes and the latest advances underlying the use of metabolic checkpoints in antitumor immunotherapies. In this context, targeting both tumor and immune cell metabolic reprogramming may enhance therapeutic efficacy.

引用

页码：534 / 547

页数：14

共 110 条

[51] Hallmarks of cancer stem cell metabolism [J].

Sancho, Patricia ;

Barneda, David ;

Heeschen, Christopher .

BRITISH JOURNAL OF CANCER, 2016, 114 (12) :1305-1312

[52] Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy [J].

Okkenhaug, Klaus ;

Graupera, Mariona ;

Vanhaesebroeck, Bart .

CANCER DISCOVERY, 2016, 6 (10) :1090-1105

[53] Novel drugs that target the metabolic reprogramming in renal cell cancer [J].

van der Mijn, Johannes C. ;

Panka, David J. ;

Geissler, Andrew K. ;

Verheul, Henk. M. ;

Mier, James W. .

CANCER & METABOLISM, 2016, 4

[54] Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent [J].

Pantziarka, Pan ;

Sukhatme, Vidula ;

Bouche, Gauthier ;

Meheus, Lydie ;

Sukhatme, Vikas P. .

ECANCERMEDICALSCIENCE, 2016, 10

[55] Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion [J].

Otvos, Balint ;

Silver, Daniel J. ;

Mulkearns-Hubert, Erin E. ;

Alvarado, Alvaro G. ;

Turaga, Soumya M. ;

Sorensen, Mia D. ;

Rayman, Patricia ;

Flavahan, William A. ;

Hale, James S. ;

Stoltz, Kevin ;

Sinyuk, Maksim ;

Wu, Qiulian ;

Jarrar, Awad ;

Kim, Sung-Hak ;

Fox, Paul L. ;

Nakano, Ichiro ;

Rich, Jeremy N. ;

Ransohoff, Richard M. ;

Finke, James ;

Kristensen, Bjarne W. ;

Vogelbaum, Michael A. ;

Lathia, Justin D. .

STEM CELLS, 2016, 34 (08) :2026-2039

[56] Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer [J].

Al-Khami, Amir A. ;

Rodriguez, Paulo C. ;

Ochoa, Augusto C. .

ONCOIMMUNOLOGY, 2016, 5 (08)

[57] Harnessing the immune system to improve cancer therapy [J].

Papaioannou, Nikos E. ;

Beniata, Ourania V. ;

Vitsos, Panagiotis ;

Tsitsilonis, Ourania ;

Samara, Pinelopi .

ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (14)

[58] Proton pump inhibitors affect the gut microbiome [J].

Imhann, Floris ;

Bonder, Marc Jan ;

Vila, Arnau Vich ;

Fu, Jingyuan ;

Mujagic, Zlatan ;

Vork, Lisa ;

Tigchelaar, Ettje F. ;

Jankipersadsing, Soesma A. ;

Cenit, Maria Carmen ;

Harmsen, Hermie J. M. ;

Dijkstra, Gerard ;

Franke, Lude ;

Xavier, Ramnik J. ;

Jonkers, Daisy ;

Wijmenga, Cisca ;

Weersma, Rinse K. ;

Zhernakova, Alexandra .

GUT, 2016, 65 (05) :740-748

[59] Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism [J].

Yang, Wei ;

Bai, Yibing ;

Xiong, Ying ;

Zhang, Jin ;

Chen, Shuokai ;

Zheng, Xiaojun ;

Meng, Xiangbo ;

Li, Lunyi ;

Wang, Jing ;

Xu, Chenguang ;

Yan, Chengsong ;

Wang, Lijuan ;

Chang, Catharine C. Y. ;

Chang, Ta-Yuan ;

Zhang, Ti ;

Zhou, Penghui ;

Song, Bao-Liang ;

Liu, Wanli ;

Sun, Shao-Cong ;

Liu, Xiaolong ;

Li, Bo-liang ;

Xu, Chenqi .

NATURE, 2016, 531 (7596) :651-+

[60] Myeloid cells in the tumor microenvironment: Role of adenosine [J].

Morello, Silvana ;

Pinto, Aldo ;

Blandizzi, Corrado ;

Antonioli, Luca .

ONCOIMMUNOLOGY, 2016, 5 (03)

← 1 2 3 4 5 6 7 8 9 10 →